No Characterization. No Party shall characterize, issue releases or certificates of analysis for, or analyze the other Party’s Program Material (including, for BN, the MVA-BN Vector, any HPV MVA-BN Vector and, for ▇▇▇▇▇▇▇, any ▇▇▇▇▇▇▇ HPV Antigen, Vector, Ad26 Vector, HPV Ad Vector and/or the HPV Ad26 Vector), or engage in any research that concerns any safety, toxicity or tumorigenicity of the other Party’s Program Materials without obtaining the prior written approval of the other Party. BN shall give written approval for any testing of its Program Materials necessary for ▇▇▇▇▇▇▇ to perform its obligations or exercise its rights under this Agreement.
Appears in 2 contracts
Sources: Collaboration and License Agreement (Bavarian Nordic a/S / ADR), Collaboration and License Agreement (Bavarian Nordic a/S / ADR)